key: cord-0830167-4cr98hdu
authors: Kalafat, Erkan; Prasad, Smriti; Birol, Pinar; Tekin, Arzu Bilge; Kunt, Atilla; Di Fabrizio, Carolina; Alatas, Cengiz; Celik, Ebru; Bagci, Helin; Binder, Julia; Le Doare, Kirsty; Magee, Laura A.; Mutlu, Memis Ali; Yassa, Murat; Tug, Niyazi; Sahin, Orhan; Drokos, Panagiotis; O’Brien, Pat; Dadelszen, Peter von; Palmrich, Pilar; Papaioannou, George; Ayaz, Reyhan; Ladhani, Shamez N.; Kalantaridou, Sophia; Mihmanli, Veli; Khalil, Asma
title: An internally validated prediction model for critical COVID-19 infection and intensive care unit admission in symptomatic pregnant women
date: 2021-09-25
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2021.09.024
sha: cd7e1d31959d069f18ed17799469347dc37161a9
doc_id: 830167
cord_uid: 4cr98hdu

Background Pregnant women are at increased risk of mortality and morbidity due to coronavirus disease 2019 (COVID-19). Many studies reported on the association of COVID-19 with pregnancy specific adverse outcomes but prediction models utilizing large cohort of pregnant women are still lacking for estimating the risk of maternal morbidity and other adverse events. Objective The main aim of this study was to develop a prediction model to quantify the risk of progression to critical COVID-19 and intensive care unit admission in pregnant women with symptomatic infection. Study design This was a multicenter retrospective cohort study including eight hospitals from four countries (UK, Austria, Greece and Turkey). Data extraction was from February 2020 until May 2021. Included were consecutive pregnant and early postpartum women (within 10 days of birth), reverse transcriptase polymerase chain reaction confirmed SARS-CoV-2 infection. The primary outcome was progression to critical illness requiring intensive care. Secondary outcomes included maternal death, preeclampsia and stillbirth. The association between the primary outcome and 12 candidate predictors with known association with severe COVID-19 in pregnancy, was analyzed with log-binomial mixed-effects regression and reported as adjusted risk ratios (aRR). All potential predictors were evaluated in one model and only baseline factors in another. Predictive accuracy were assessed by the area under the receiver operating characteristic curves (AUROC). Results Of 793 pregnant women positive for SARS-CoV-2 and symptomatic, 44 (5.5%) were admitted to intensive care, of whom 10 died (1.3%). The ‘mini-COvid Maternal Intensive Therapy’ model included demographic and clinical variables available at disease onset: maternal age (aRR: 1.45, 95% CI: 1.07–1.95, P=0.015); body-mass index (aRR: 1.34, 95% CI: 1.06–1.66, P=0.010); and diagnosis in the third trimester of pregnancy (aRR: 3.64, 95% CI: 1.78–8.46, P=0.001). The optimism-adjusted AUROC was 0.73. The ‘full-COvid Maternal Intensive Therapy’ model included body-mass index (aRR: 1.39, 95% CI: 1.07–1.95, P=0.015), lower respiratory symptoms (aRR: 5.11, 95% CI: 1.81–21.4, P=0.007), neutrophil/lymphocyte ratio (aRR: 1.62, 95% CI: 1.36–1.89, P<0.001); and serum C-reactive protein (aRR: 1.30, 95% CI: 1.15–1.44, P<0.001), with an optimism-adjusted AUROC 0.85. Neither model showed signs of poor fit (P>0.05). Categorization as high risk by either model was associated with a shorter diagnosis to ICU admission interval (log-rank test P<0.001, both), higher maternal death (5.2% vs. 0.2%; P<0.0001) and preeclampsia (5.7% vs. 1.0%; P=0.0003). A spreadsheet calculator is available for risk estimation. Conclusion At presentation with symptomatic COVID-19, pregnant and recently postpartum women can be stratified into high and low-risk for progression to critical disease, even where resources are limited. This can support the nature and place of care. These models also highlight the independent risk for severe disease associated with obesity, and should further emphasize that even in the absence of other co-morbidities, vaccination is particularly important for these women. Finally, the model also provides useful information for policy makers when prioritizing national vaccination programmes to quickly protect those at highest risk of critical and fatal COVID-19.

available at disease onset: maternal age (aRR: 1.45, 95% CI: 1.07-1.95, P=0.015); 1 body-mass index (aRR: 1.34, 95% CI: 1.06-1.66, P=0.010); and diagnosis in the third 2 trimester of pregnancy (aRR: 3.64, 95% CI: 1.78-8.46 associated with a shorter diagnosis to ICU admission interval (log-rank test P<0.001, 10 both), higher maternal death (5.2% vs. 0.2%; P<0.0001) and preeclampsia (5.7% vs. 11 1.0%; P=0.0003). A spreadsheet calculator is available for risk estimation. care. These models also highlight the independent risk for severe disease associated 16 with obesity, and should further emphasize that even in the absence of other co-17 morbidities, vaccination is particularly important for these women. Finally, the model 18 also provides useful information for policy makers when prioritizing national vaccination 19 programmes to quickly protect those at highest risk of critical and fatal COVID-19. The presentation of coronavirus disease 2019 is quite variable, ranging 2 from asymptomatic infection to mild respiratory illness with minimal supportive care, to 3 hospitalization with multi-organ failure and death 1, 2 . Given alterations in physiology 4 and immune function (e.g., inflammatory or prothrombotic markers) that may mask or 5 predispose to severe-critical disease, pregnant women represent a unique population 6 compared to their non-pregnant peers 3 . 7 To reduce the burden on healthcare resources and focus them on those in greatest 8 need, it is important to identify individual patients at increased actuarial risk of 9 progression to critical COVID-19. Several COVID-related outcome prediction models, 10 based on clinical, laboratory and imaging criteria, have been developed for the general 11 population 4-6 . However, they have methodological limitations and do not account for 12 pregnancy, limiting their generalizability and applicability 7 . Furthermore, some models 13 rely heavily on radiologic investigations that are less frequently employed in 14 pregnancy, particularly when symptoms are mild. 15 Emerging data from the United Kingdom and United States suggest that pregnant 16 women may be experiencing more severe illness in the second wave of the pandemic 17 compared with the first 8, 9 . A recent living systematic review of maternal and fetal 18 outcomes in pregnant women found that, although these women are less likely to 19 report symptoms of COVID-19, they are more than twice as likely as their non-pregnant 20 peers to require critical care or mechanical ventilation 3 , a finding corroborated by large 21 national registries such as Central for Disease Control (CDC) 9 . 22 The main aim of this study was to develop a prediction model to quantify the risk of This was a multicenter cohort study including the following seven centers in four 2 countries (Table S1 ). Data extraction was from the start of the pandemic in each 3 country to 1 st of May 2021. Relevant data were extracted from electronic patient 4 records and anonymized for statistical analysis.

The inclusion criteria were pregnant and early postpartum women (within 10 days of 6 birth), reverse transcriptase polymerase chain reaction (RT-PCR)-confirmed SARS-7 CoV-2 infection. Included women had mild, moderate or severe illness at the time of 8 diagnosis. The exclusion criteria were asymptomatic infection (positive RT-PCR for 9 SARS-CoV-2 without any clinical symptoms); critical illness at the time of diagnosis; 10 prior COVID-19 infection; or been vaccinated against SARS-CoV-2. All included 11 women were either followed up as outpatients or admitted as an inpatient for supportive 12 care. Women without critical illness or outpatients were followed-up for 14 days 13 following the diagnosis of COVID-19. Patients were managed according to local 14 protocols.

Symptomatic RT-PCR-positive pregnant/postpartum women but without lower 16 respiratory tract symptoms (e.g., dyspnea) or abnormal chest imaging (i.e., 17 tomography, lung ultrasound, or chest X-ray) were classified as having mild illness.

Moderate illness was diagnosed in RT-PCR-positive pregnant/postpartum women with 19 lower respiratory tract symptoms without significant hypoxia (pulse oximetry saturation 20 ≥94%). Severe illness was diagnosed in RT-PCR-positive pregnant/postpartum 21 women with oxygen saturation <94%, respiratory rate >30 breaths per minute, partial 22 pressure of oxygen to fraction of inspired oxygen <300mmHg, but not meeting the 23 criteria for critical illness. Critical illness was diagnosed in patients with acute 24 respiratory distress syndrome (ARDS) requiring mechanical ventilation support, septic shock, cardiac dysfunction, hyper-inflammatory syndrome, or other organ system 1 dysfunction 1 .

2 Data on maternal age, self-reported ethnicity, body mass index (BMI), smoking, 3 chronic co-morbidities (pregestational diabetes, chronic hypertension, heart disease 4 [valvular, arrhythmia or cardiomyopathy] and bronchial asthma), gestational age at 5 diagnosis, number of fetuses, and hospitalization were collected. When available, 6 complete blood count (CBC) and C-reactive protein (CRP) assessment at the time of 7 diagnosis were also collected. We did not collect data related to gestational diabetes 8 due to variability in screening and diagnosis between centers. Candidate variables 9 were selected among the factors with known or plausible associations with severe 10 COVID-19 in pregnant and non-pregnant adult populations.

The primary outcome was progression to critical illness requiring intensive care unit 12 (ICU) admission. Secondary outcomes were maternal death, preeclampsia and 13 stillbirth. Preeclampsia was defined according to the revised criteria of the International 14 Society for the Study of Hypertension in Pregnancy 2014 Statement 10 ; hypertension 15 was defined as new-onset systolic blood pressure ≥140 mmHg and/or diastolic blood 16 pressure ≥90 mmHg, on two occasions more than 24 hours apart. Proteinuria was 17 defined as a protein/creatinine ratio ≥30mg/mmol or a 24-hour urine collection with 18 ≥300mg/24 hours. Stillbirth was defined as fetal death at or beyond 24 +0 weeks' Effect size was reported as mean, median difference or odds ratio (OR) and 95% 3 confidence intervals (CI). Association of variables with ICU admission was analyzed 4 with log-binomial mixed-effects regression and reported as adjusted risk ratios (aRR).

Risk estimates in the regression were reported for one standard unit change in the 6 respective variables. Random intercepts were used to account for study center-level 7 variance. 8 Prediction models were built using generalized linear models using logit link function.

Two predictive models were constructed from candidate predictors associated with 10 more severe COVID-19 in or outside pregnancy. The first model used demographic Of 793 pregnant/postpartum women who were positive for SARS-CoV-2 by RT-PCR 2 and symptomatic, 44 (5.5%) women were admitted to ICU, of whom 10 died (1.3%).

3 Table S2 shows that many baseline characteristics varied between women admitted 4 to ICU versus those who were not. Women admitted to ICU were significantly older, 5 and just over (vs under) 30 years of age. They were more often obese (one-third) and 6 smokers (almost 7%). There were no differences in either ethnicity (most women 7 overall were White) or chronic morbidities. Women admitted to ICU were at a more 8 advanced gestational age (by just over three weeks), more likely to be in their third 9 trimester and have lower respiratory tract symptoms. Most women had singleton 10 pregnancies. There were 658 women (83.0%) who had laboratory assessment with 11 CBC and serum CRP at diagnosis with COVID-19. Women admitted to the ICU (vs. 12 those who were not) had significantly higher absolute neutrophil counts, lower 13 lymphocyte counts, and higher neutrophil/lymphocyte ratios, in addition to higher CRP. 14 Most women who were not admitted to ICU were still hospitalized.

15 Table 1 shows that by univariable regression analysis, all of the following were 16 associated with ICU admission (p<0.05): clinical characteristics of maternal age, BMI, 17 smoking, chronic co-morbidities, gestational age at diagnosis of COVID-19, third 18 trimester pregnancy, and lower respiratory tract symptoms; and laboratory test results

showing anemia, lymphopenia, higher neutrophil/lymphocyte ratio and higher CRP 20 levels.

The miniCOMIT model (based on N=786 women, 7 excluded for missing data for one to ICU admission interval (log-rank test P<0.001, Figure 2 ). These women more often In this multicenter international prospective cohort study, we were able to identify 3 women at increased risk of severe COVID-19, based on variables at symptom onset 4 and particularly those at hospital admission. Risk stratification by either model was 5 able to classify women into high-and low-risk categories with systematic differences 6 in the rates of ICU admission, maternal death, and preeclampsia. fullCOMIT has good 7 performance as a rule-out test for ICU admission (LR-≤0.20), and both miniCOMIT 8 and fullCOMIT have good and very good performances as rule-in tests once risks are 9 estimated to be 10%-24.9%, respectively. High-risk women also had a shorter time We noted an increase in the prevalence of preeclampsia in the cohort predicted to be 3 at high-risk of ICU admission and death by our model. Studies have reported an 4 increased rate of preeclampsia in women with COVID-19 but did not demonstrate a 5 link with COVID-19 severity 21 . Finally, the rate of stillbirth was twice as high in the 6 group categorized as high risk for COVID-19, but this difference was not statistically 7 significant. This finding is likely to be related to low numbers and inadequate statistical Limitations do apply to our findings. First, we were probably underpowered to look at 20 the impact of ethnicity (Black or other ethnic minority groups) or maternal comorbidities 21 on maternal ICU admission with symptomatic COVID-19 infection. Second, being 22 relatively underpowered resulted in no women being rated with a miniCOMIT risk 23 ≥50%. Third, we did not include chest imaging (using ionizing radiation or alternatives 1 in pregnancy, and we aimed to develop a generalizable model. However, the inclusion 2 of imaging modalities would probably increase the predictive accuracy. Fourth, we did 3 not perform external validation due to the constraints of our sample size. Dataset 4 partitioning would have caused the model to overfit and yield biased estimates due to 5 oversaturation. Instead, we opted to use the whole cohort for model building and 6 adjusting for optimism via cross-validation, which is the recommended approach 11,12 . 7 There are numerous international cohorts of pregnant women published in the 8 literature, so external validation can be performed in future studies with relative 9 ease 24,25 . Fifth, we did not account for treatments applied in each center in the model. 

The use of this baseline characteristics prediction model will enable the vaccine program to prioritize those pregnant women at greatest risk. Targeted prioritization for 1 vaccination will be of key importance in all countries around the world, not just in the 2 current vaccine roll out, but also for future iterations of the vaccine directed at new 3 variants of the virus. This will be essential in settings and populations where the 4 availability of a suitable vaccine or the infrastructure to support a rapid mass 5 vaccination program may be limited. -5.1% (-7.9 --2.0%) -Afro-Caribbean 21 (2.8) 4 (9.1) 6.3% (-2.2 -14.9%) -Asian 9 (1.2) 0 (0.0) -1.2% (-2.0 --0.4%) -Not reported 2 (0.3) 0 (0.0) Chronic comorbidity (one/more) 49 (6.5) 6 (13.6) 7.1% (-3.1 to 17.3%) 0.079 -Pre-pregnancy diabetes 9 (1.2) 2 (4.5) 3.4% (-2.8 -9.6%) -Chronic hypertension 8 (1.1) 1 (2.3) 1.2% (-0.9 to 2.9%) -Heart disease 3 (0.4) 0 (0.0) -0.4% (-0.8 -0.5%) -Bronchial asthma 33 (4.4) 4 (9. 

Sensitivity, specificity, and predictive values calculated using the upper limit of the risk range to define a positive test. CI: confidence interval, LR: likelihood ratio, NPV: negative predictive value, PPV: positive predictive value, COMIT: COvid Maternal Intensive Therapy

Clinical and radiologic characteristics of symptomatic pregnant women with COVID-19 pneumonia

Epub ahead of print

Anxiety levels and obsessive compulsion symptoms of pregnant women during the COVID-19 pandemic

Pregnancy worsens the morbidity of COVID-19 and this effect becomes more prominent as pregnancy advances

Utility of lung ultrasound assessment for probable SARS-CoV-2 infection during pregnancy and universal screening of asymptomatic individuals